阿斯利康(AZN.US)1類新藥首次在中國獲批臨牀 擬開發治療心力衰竭
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
恆生指數收報19,423升56點 成交額...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...